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Atrial natriuretic peptjde kinetic studies in patients with cardiac
dysfunction. Three studies were performed: (1) a controlled investiga-
tion of a-human atrial natriuretic peptide (a-hANP) total body produc-
tion and metabolic clearance rates using a bolus infusion technique
(controls, patients I to 6); (2) a study of a-hANP kinetics in cardiac
dysfunction patients using a constant infusion method (patients 7 to 14);
and (3) a right heart catheterization study to determine the amount of
a-hANP released into the circulation at the level of the right heart,
estimated by the step-up in a-hANP concentration between the superior
and inferior vena cava and the pulmonary artery, in the patients with
left ventricular dysfunction. Baseline venous plasma a-hANP was 27.3
16.5 pg/mI in the controls (mean SD; N = 6), 141.6 138.0 pg/mI
in patients I to 6 (P < 0.05 compared to controls), and 167.5 145.7
pg/mI in patients 7 to 14. Total body a-hANP production rate was
markedly elevated in patients I to 6 compared to controls (0.45 0.36
vs. 0.11 0.06 g/min, P < 0.05) and was similar to that determined by
the continuous infusion technique in patients 7 to 14 (0.62 0.44
g/min, P = 0.49 compared to patients ito 6). a-hANP release into the
right heart (0.17 0.11 jg/min), however, was significantly lower than
total body production rate in the cardiac dysfunction patients, indicat-
ing that total body a-hANP secretion occurs from sites in addition to
drainage into the right heart via the coronary sinus and anterior cardiac
veins. Right atrial pressure correlated with the a-hANP released into
the right heart. We conclude that in our patients with left ventricular
dysfunction, increased a-hANP production was the major factor con-
tributing to the elevated plasma a-hANP concentrations; moreover,
considerable amounts of a-hANP were also secreted into the circulation
at sites other than the right heart.
Circulating concentrations of plasma a-human atrial natri-
uretic peptide (a-hANP) are elevated in pathological states
associated with increased atrial pressures, volume overload,
and/or venous congestion, such as congestive heart failure
[1—4]. In patients with cardiac dysfunction, the degree of plasma
a-hANP elevation approximates the clinical severity of the
heart failure [1] and strongly correlates with right and left atrial
pressures [1—4]. These findings are consistent with the hypoth-
esis that cardiac secretion of a-hANP occurs primarily via the
coronary sinus into the right atrium in response to distension of
the atria [5, 6]. However, two recent investigations suggest that
cardiac release of a-hANP into the right heart is not the sole
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source of circulating a-hANP in heart failure patients [7, 8].
These studies demonstrated a significant step-up in plasma
a-hANP concentrations from the pulmonary veins to the aorta
in a majority of patients studied with New York Heart Associ-
ation (NYHA) Class II to IV heart failure, suggesting that
a-hANP is also released into the circulation directly at the level
of the left heart [7, 81. To date, the quantitative contribution to
circulating a-hANP from sites other than the coronary sinus
into the right atrium has not been established. The contribu-
tion(s) of increased secretion and/or decreased clearance of
a-hANP in patients with left ventricular dysfunction has also
not been assessed.
Thus, the present studies were undertaken to compare total
body production and metabolic clearance rates of a-hANP
between heart disease patients and control subjects and to
determine the amount of a-hANP released into the right heart
as compared to total body a-hANP production in patients with
cardiac dysfunction. Three studies were performed: (1) a con-
trolled investigation of a-hANP kinetics using a bolus infusion
technique; (2) a study of a-hANP kinetics in cardiac dysfunc-
tion patients using a constant infusion method; and (3) a right
heart catheterization study to determine the amount of a-hANP
released into the circulation at the level of the right heart in
patients with left ventricular dysfunction.
Methods
The studies were performed under the auspices of a Notice of
Claimed Investigator Exemption for a New Drug from the U.S.
Food and Drug Administration sponsored by one of us (RWS).
The studies were approved by the Human Subjects Committees
of both institutions and were performed after written informed
consent had been given. All studies at both institutions were
supervised by one of us (JH).
Subjects
In all, fourteen patients with cardiac dysfunction and six
normal controls were studied. The a-hANP bolus kinetic study
was performed in the six control subjects and patients 1 to 6 at
the Clinical Research Center of the University of Colorado
School of Medicine. The a-hANP continuous infusion study
was performed in patients 7 to 14 at the Freie Universität
Berlin. Thirteen of the fourteen patients with cardiac dysfunc-
tion participated in the right heart catheterization study, The
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Table 1. Characteristics of the patients with cardiac dysfunction
Age NYHA LVEFb Edema, S3 CO RAP
Patienta Diagnosis years Sex class % or rales liter/mm mm Hg
1 IHD 57 M IV 31 +++ 4.49 12
2 IHD 50 M III 22 + 3.50 8
3 IDCM 53 F II 30 4.80 2
4 AVR 60 M II 34 4.22 3
5 IHD 48 F III 25 ++ 4.99 8
6 IHD 40 F III 26 ++ C
7 IHD 70 M IV 16 +++ 4.63 7
S IDCM 60 F II 34 4.12 0
9 IDCM 57 M III 16 + 3.85 2
10 IDCM 47 M III 20 + 3.78 7
11 IDCM 62 M IV 15 + 2,42 6
12 IDCM 58 F III 24 ++ 3.87 3
13 IDCM 62 M II 45 4.44 0
14 IDCM 62 M III 17 4.93 2
Abbreviations are: AVR, aortic valve replacement; CU, cardiac output; IDCM, idiopathic dilated cardiomyopathy; IHD, ischemic heart disease;
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RAP, right atrial pressure; S3. third heart sound.
U Patients 1 to 6 studied in Denver; patients 7 to 12 studied in Berlinb LVEF by radionuclide ventriculography
C Patient 6 not catheterized
characteristics of the heart disease population are shown in
Table 1. Eight patients had idiopathic dilated cardiomyopathy,
five had ischemic heart disease, and one had aortic valve
disease. Their ages ranged from 40 to 70 years, with a mean of
56.1 7.8 years. Nine of the patients were male. By NYHA
criteria, the patients' functional classifications ranged from
Class II to IV; four were Class II, seven were Class III, and
three were Class IV. All patients had documented cardiac
dysfunction with a reduced left ventricular ejection fraction of
less than or equal to 45% by gated blood pool scan performed at
the time of study. All patients had previous episodes of pulmo-
nary edema, and nine were decompensated at the time of study
as judged by the presence of one or more of the following
physical findings: edema, pulmonary rates, or a third heart
sound. All patients had a cardiac output of less than 5 liters/mm
at the time of study as determined by the thermodilution
method. Right atrial pressures ranged from 0 to 12 mm Hg, and
pulmonary capillary wedge pressures ranged from 5 to 35 mm
Hg. They all required treatment with loop diuretics, and most
patients were also treated with angiotensin converting enzyme
inhibitors and digoxin. With the exception of five patients with
hypertension, the heart disease patients were free of other
morbid states; specifically, no patient had advanced renal
insufficiency (serum creatinine: range 0.6 to 1.3 mg/dl at the
time of study), chronic obstructive pulmonary disease, or
chronic liver disease. Tricuspid valve insufficiency was ex-
cluded by Doppler echocardiography.
The normal subjects were six healthy volunteers (5 male, 1
female), on no medication, and ranged in age from 32 to 60
years (mean 43.3 9.6 years).
Study protocol
Diuretics, angiotensin converting enzyme (ACE) inhibitors,
and digoxin were withdrawn at least one day, and in most cases
four days, prior to admission into the study. All subjects,
patients and controls, underwent a-hANP kinetics studies to
determine total body -hANP production and metabolic clear-
ance rates. In the first study, the metabolic clearance rate was
determined by bolus injection of a-hANP in cardiac dysfunction
patients and in normal controls as described below. To control
for the possibility of a-hANP receptor saturation associated
with the excess of s-hANP infused during the bolus study, a
second study was performed in eight additional heart disease
patients to assess metabolic clearance rate by continuous
infusion of s-hANP at a dose within the physiologic range seen
in heart failure patients. Right heart catheterization was per-
formed in thirteen of the patients with cardiac dysfunction to
estimate a-hANP release into the right heart as described
below.
Bolus study
The a-hANP bolus kinetic study was performed in six pa-
tients with cardiac dysfunction and in the six normal subjects.
The study was performed in the supine position after an
overnight fast and a light breakfast (toast, butter, marmalade,
and one cup of decaffeinated tea or coffee). One hour prior to
study, short plastic 18-gauge intravenous catheters were intro-
duced into each antecubital vein. One arm was designated for
obtaining venous blood samples; the other arm was reserved for
the ct-hANP injection. At 8:00 a.m., baseline blood samples
were drawn. Immediately thereafter, 100 g of a-hANP
(ANP12, Merck Sharp & Dohme, West Point, Pennsylvania,
USA) was injected as a bolus. Blood was drawn at 2, 4, 7, 10,
15, 30, 45, 60, and 90 minutes after injection for determination
of ts-hANP concentration. After the baseline a-hANP level had
been subtracted, the data were fitted using a nonlinear curve
fitting program [91. Metabolic clearance rate was calculated by
dividing the area under the curve by injected dose body
weight. Production rate was calculated from metabolic clear-
ance rate• [a-hANP1pias,a . body weight.
Continuous infusion study
The a-hANP continuous infusion kinetic study was per-
formed in eight heart disease patients. The study was performed
in the supine position, one hour after right heart catheterization.
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Alpha-hANP (ANP9126, Bissendorf Peptide, Wedemark, Ger-
many) was given by an infusion pump (Perfusor, Braun, Mel-
sungen, Germany) at a constant rate of 1 g/min via a forearm
vein for one hour. Steady-state blood samples were obtained
from an indwelling femoral vein catheter at 40, 50, and 60
minutes for determination of a-hANP concentration. Metabolic
clearance rate was calculated from the mean steady-state
a-hANP concentration during continuous infusion divided by
infusion rate body weight. Production rate was calculated
from metabolic clearance rate• [a-hANPIp,asma body weight.
Right heart catheterization study
On the same day as the a-hANP kinetic study, the right heart
catheterization study was performed in thirteen of the fourteen
patients with cardiac dysfunction. A 7F triple-lumen, flow-
directed, balloon-tipped thermodilution catheter (Edwards Lab-
oratories, Santa Ana, California, USA) was advanced into the
pulmonary artery from either the femoral or right internal
jugular veins. Cardiac output was determined using the ther-
modilution method with iced 5% dextrose in water. Blood for
determination of a-hANP was drawn from the inferior vena
cava (IVC), superior vena cava (SVC), and pulmonary artery
(PA); catheter placement was confirmed by fluoroscopy in each
instance. In a subset of patients (N = 11), a-hANP levels were
measured in blood samples from the femoral vein and femoral
artery (FA).
The amount of a-hANP released into the right heart was
calculated by subtracting the estimated amount of a-hANP
returning to the right heart from the superior and inferior vena
cava [plasma cardiac output ((3 a-hANPjvc + 1
hANP)/4)j from the amount of -hANP transported into the
pulmonary arteries (plasma cardiac output• a-hANPPA).
Plasma cardiac output was calculated using the formula: cardiac
output [(lOO-Hct)/l00j. The data were also analyzed by giving
different weights to the individual contributions of the SVC and
IVC to the amount of a-hANP returning to the right heart;
however, the results were not significantly affected and are
reported only for the formula detailed above.
a-hA NP assay
Blood samples were collected in chilled tubes containing
EDTA and aprotinin, immediately centrifuged, and the plasma
was stored at —80°C until the time of assay. Plasma concentra-
tions of ANP99126 (a-hANP) were measured by radioimmuno-
assay following extraction onto Sep-Pak C18 cartridges (Waters
Associates, Milford, Massachusetts, USA) as previously de-
scribed [10, 11]. The a-hANP antibody used (Peninsula Labo-
ratories, Belmont, California, USA) is highly specific for the
ring structure and intact C-terminal portion of the molecule.
The cross reactivities between this antibody and I3ANP and
TANP are 50% and 40%, respectively. Serial dilutions at 1:5 and
1:10 were used to assess for contamination by such cross
reacting peptides.
Statistical analysis
Single comparisons of means were performed by t-tests.
Mann-Whitney's test was used for data that were not distrib-
uted normally. The correlation studies were performed by
least-squares regression analysis. The results are expressed as
Table 2. Blood pressure and heart rate before and during a-hANP
infusion in patients with cardiac dysfunction and in control subjectsa
During 100 g
Baseline a-hANP"°
BP HR BP HR
mm Hg bp,n mm Hg bpm
Control
1 134/84 88 132/80 86
2 140/86 92 140/88 88
3 106/70 108 100/72 100
4 132/66 80 136/70 84
5 120/84 80 128/88 80
6 128/80 64 120/80 60
Mean SD 127/78 78 126/80
1 132/100 110 138/98 112
2 140/108 92 149/102 98
3 125/74 90 132/78 102
4 148/94 112 160/94 100
5 114/80 84 114/78 80
6 108/68 81 120/70 88
Mean SD 128/87 95 136/87 97
Patient
7 139/70 81 140/70 83
8 156/77 102 164/91 106
9 134/72 60 133/65 58
10 130/97 105 125/99 97
11 93/58 81 90/54 82
12 105/78 71 112/88 79
13 131/87 93 123/88 99
14 152/78 116 158/81 100
Mean SD 130/77 89 131/80 88
Abbreviations are: BP, blood pressure (systolic/diastolic); HR, heart
rate in beats per minute (bpm).
a Patients 1 to 6 studied in Denver; patients 7 to 12 studied in Berlinb Determined 10 minutes after bolus a-hANP injection in patients I
to 6
Determined after 60 minutes (steady state) of continuous a-hANP
infusion in patients 7 to 12
the mean SD. The statistical level of significance was P < 0.05
for all tests.
Results
Total body a-hANP kinetics
All patients with cardiac dysfunction remained clinically
stable throughout the studies, with a stable blood pressure and
heart rate (Table 2). No adverse effects were observed in any
subject after bolus injection or during continuous infusion of
a-hANP.
Baseline venous plasma a-hANP concentrations. Basal
venous plasma a-hANP was 27.3 16.5 pg/ml in the controls
(N = 6), 141.6 138.0 pg/ml in the patients 1 to 6 (N = 6, P <
0.05 compared to controls), and 167.5 145.7 pg/mi in patients
7 to 14 (N = 8,P < 0.05 compared to controls). There was no
difference in basal venous plasma a-hANP concentrations
between the patients studied in Denver and those studied in
Berlin (P = 0.76), and the mean basal venous plasma a-hANP
level for all heart disease patients was 156.6 143.1 pglml(N =
14, P = 0.01 compared to controls).
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Fig. 1. Mean plasma disappearance curves of a-hANP after intrave-
nous bolus injection of 100 g a-hANP at time 0. N = 6 in each group.
Symbols are: (— — —) controls; (—) patients.
Bolus study. Two minutes after injection, mean plasma levels
of a-hANP reached 4095.5 1805.1 pg/ml in the controls (N
6) and 3740.2 1146.8 pg/mI in the patients (N = 6; P = 0.69),
as shown on Figure 1. When the time course of immunoreactive
a-hANP was drawn on a logarithmic scale, no straight line
could be fitted through the data points. Data fitting by a
nonlinear curve fitting program yielded significantly better fits
for all subjects for a bi-exponential model (a-hANPpiagma (t) =
A- e + B e t) than for a mono-exponential model
(a-hANPp1 (t) = A e' 1)
The data were further analyzed using the open two-compart-
ment model, where elimination only occurs through the central
compartment [121. The mean initial volume of distribution was
14.9 6.2 1(18.9 2.8% of body wt) in the controls and 14.4
5.4 1 (17.9 3.3% of body wt) in the patients (P = 0.89). A
significant difference was observed between controls and heart
disease patients for production rate (0.11 0.06 vs. 0.45 0.36
g/min, P < 0.05), but not for t172 (1.95 0.21 vs. 2.02 0.28
mm, P = 0.66), t112 (15.46 1.69 vs. 33.86 26.20 mm, P
0.15), and metabolic clearance rate (55.8 13.3 vs. 45.4 15.3
ml min kg_i, P = 0.28).
Continuous infusion study. The mean steady-state venous
plasma a-hANP concentration during the infusion was 402
204 pg/mI (N = 8), a value within the basal range for patients
with decompensated left ventricular dysfunction. With this
technique, the metabolic clearance rate in eight patients
with cardiac dysfunction was calculated to be 57 22
ml . min' . kg', a rate that was not significantly different than
that calculated after bolus injection of a-hANP in either cardiac
dysfunction patients (45.4 15.3 ml - mm' kg', P = 0.32)
or control subjects (55.8 13.3 ml min . kg', P = 0.91).
Production rate was calculated to be 0.62 0.44 g/min for the
cardiac dysfunction patients, a value not statistically different
than that determined by bolus injection in the patients (0.45
0.36 g/min, P 0.49).
Right heart catheterization study
Basal venous plasma a-hANP concentration averaged 126.5
98.2 pg/mI at the time of right heart catheterization in the
thirteen patients studied and did not differ from baseline
a-hANP levels assessed at the time of the kinetics studies (154.6
Table 3. a-hANP concentrations from right heart catheterization in
cardiac dysfunction patients
Patienta
cs-hANP concentration pg/mi
IVC SVC PA FA Veinb
1 221 270 361 278 213
2 76 198 215 223 202
3 21 39 48 39 38
4 27 76 90 — 53
5 126 145 195 — 88
7 157 249 282 399 173
8 24 29 62 65 25
9 142 108 161 181 74
10 265 200 395 435 155
Ii 382 480 583 390 364
12 197 284 304 354 202
13 18 11 31 21 18
14 39 55 55 62 40
Abbreviations are: FA, femoral artery; IVC, inferior vena cava; PA,
pulmonary artery; SVC, superior vena cava. Excludes Patient 6 (not
catheterized).
a Patients I to 5 studied in Denver; patients 7 to 12 studied in Berlin
b Venous samples from either femoral vein (Berlin patients) or
peripheral arm vein (Denver patients)
148.3 pg/mI, P = 0.59, Table 3), Mean plasma a-hANP
concentrations in the IVC, SVC, and PA were 130 108, 165
129, and 214 160 pg/mI, respectively (N = 13). Of note, in the
subset of patients in whom femoral artery (FA) a-hANP con-
centrations were determined, FA a-hANP concentration (222
151 pglml) was the same as that measured in the PA (227 169
pg/mi, P = 0.95, N = 11). Moreover, the calculated a-hANP
release into the right heart (0.17 0.11 sg/min) was signifi-
cantly lower than total body production rate (0.51 0.41
sg/min, P < 0.01, N = 13), as shown in Figure 2, accounting for
33% of total body a-hANP production.
A positive correlation was seen between right atrial pressure
and plasma a-hANP concentration in the PA (r = 0.65, P =
0.01, N = 13). Correlation was best between right atrial
pressure and calculated a-hANP release into the right heart (r =
0.86, P <0.0001, N = 13; Fig. 3). Plasma a-hANP and a-hANP
release into the right heart likewise correlated with PCWP.
There was no correlation between right or left atrial (PCWP)
pressures and the component of cx-hANP production not re-
leased into the right heart.
cs-I-iA NP assay
ANP immunoreactivity over a five- to tenfold dilution range,
assessed on blood samples drawn both centrally and peripher-
ally, consistently fell along the standard curve for a-hANP (data
not shown).
Discussion
The present study confirms previous reports of elevated
plasma cs-hANP concentrations in patients with left ventricular
dysfunction tl—4]- The elevated venous plasma a-hANP con-
centrations seen in our patients were primarily dependent on
increased a-hANP production rates. This was shown using two
independent methods of determining a-hANP kinetics, that is,
bolus injection and continuous infusion methods.
Metabolic clearance rates of cs-hANP were not significantly
different between cardiac dysfunction patients and normal
0 30 60 90
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subjects. The calculated half-lives for the fast and slow compo-
nents (open two-compartment model) and the calculated meta-
bolic clearance of a-hANP found for controls and patients are in
good agreement with previously published data in normal
subjects [13, 14]. The variance found for the slow component of
a-hANP clearance in the patient group was due primarily to two
outliers, patients 1 and 5. When these two patients were
excluded from analysis, t12 was calculated to be 17.59 5.54
minutes, a value even closer to that found in controls. Patients
1, 2, 5, and 6 were decompensated at the time of study, and
taken together these decompensated patients tended to have a
more prolonged t112, suggesting that the metabolic clearance
rate may be prolonged in some patients with advanced, decom-
pensated cardiac dysfunction. A larger group of patients with
advanced cardiac failure would be required to further evaluate
this possibility.
In the present study, there was no evidence of a-hANP
clearance receptor saturation with the excess of a-hANP in-
fused during bolus injection since the lower plasma a-hANP
levels in the low-dose, continuous infusion technique were
associated with similar metabolic clearance rates. The mean
steady-state venous plasma a-hANP concentration during the
continuous infusion was 402 204 pg/mi, a value within the
range seen in patients with decompensated left ventricular
dysfunction.
All patients remained clinically stable throughout the period
of a-hANP administration as assessed by stable blood pressure
and heart rate responses. The withdrawal of digoxin, diuretics,
and ACE inhibitors in these patients may have resulted in
increased cardiac pre- and after-load. This possible increase in
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cardiac filling pressures would serve as a further stimulus to
a-hANP production and release.
Another important finding of the study is the demonstration
of a marked difference between the quantity of a-hANP re-
leased into the right heart and total body a-hANP production.
Overall, the calculated release of a-hANP into the right heart
accounted for only 33% of total body a-hANP production.
Rodeheffer et al [7] first suggested that the release of a-hANP
into the right heart could not be the sole source of a-hANP in
heart disease patients. This inference was based on the ob-
served step-up in plasma a-hANP concentrations from the
pulmonary veins to the aorta in their patients with NYHA Class
II to IV heart failure, suggesting that -hANP is also released
into the circulation directly at the level of the left heart [7].
Recently, Hollister et al [8] reported nearly equal a-hANP
concentrations in the pulmonary artery and aorta with a step-up
between the pulmonary vein and aorta in patients with various
forms of heart disease including those with left ventricular
dysfunction. This finding also suggests that a-hANP may be
directly released into the left heart in heart disease patients and
counterbalance the a-hANP clearance in the lung. The present
results are also compatible with that interpretation, since there
was no difference between pulmonary artery and femoral artery
a-hANP concentrations. The present results represent the first
quantitative determination of the contribution to circulating
c-hANP from sites other than the coronary sinus into the right
atrium.
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Fig. 2. Calculated a-hANP release into the right heart (open bar) and
contribution from sites other than the right heart (solid bar) expressed
as a percentage of total body cr-hA NP production in patients with left
ventricular dysfunction. Mean values in the 13 patients are shown, P =
0.01.
Right atrial pressure, mm Hg
Fig. 3. A. Correlation between right atrial pressure and release of
a-hA NP into the right heart in patients with left ventricular dysfunction(r = 0.86, P < 0.0001). II. Lack of correlation between right atrial
pressure and residual a-hANP release in the same heart failure patients(r = 0.34, P = 0.26). N = 13.
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In the present study, the calculation for production rate
assumes that metabolic clearance rate and plasma concentra-
tion have been determined for exactly the same substance, that
is ANP99 126 (a-hANP). However, immunoreactive ANP mea-
surements in plasma may detect more than just cw-hANP alone
[5]. Various fragments of ANP99126 are detectable in mamma-
lian plasma [15] and may cross react with the radioimmunoas-
say (RIA) used in the present study. In vitro studies in the rat
suggest that the ANP prohormone, proANP1126, may be re-
leased into the circulation and cross react with the RIA for
ANPJ26 [16]. Moreover, high performance gel permeation
chromatography and reverse phase high pressure liquid chro-
matography (HPLC) coupled with RIA for ANP performed in
atrial tissue obtained from failing human hearts demonstrate
that total immunoreactive ANP concentration is increased
secondary to an increase in /3-ANP, a dimer of a-hANP, as well
as to increased a-hANP [17].
Studies in normal human plasma employing HPLC tech-
niques have however demonstrated that 90 to 100% of immu-
noreactive ANP is attributable to ANP99126 [14, 18]. This
predominance of a-hANP in the circulation has been confirmed
in patients with edematous disorders, including cirrhosis [19]
and heart failure (Hollister AS, personal communication). The
non-identical behavior of immunoreactivity over serial dilutions
is commonly used to assess for the presence of cross reacting
peptides [20]. In the present studies, ANP immunoreactivity
over a five- to tenfold dilution range, assessed on blood samples
drawn both centrally and peripherally, consistently fell along
the standard curve for a-hANP indicating that the predominant
form of immunoreactive ANP measured was indeed ANP99126.
Thus, while we cannot entirely exclude a contribution of
immunoreactive ANP fragments to the present results, based
on reported results of HPLC and on our multiple dilution
curves, any contribution of such fragments must have been
small and unlikely to have affected the results obtained to any
significant degree.
Although a source in addition to the right heart was incrimi-
nated, the present results cannot ascertain whether extracar-
diac sources contribute to circulating a-hANP in patients with
left ventricular dysfunction. Immunoreactive ANP and/or ANP
mRNA has been found in various extracardiac tissues [2 1—25].
The synthesis, and in some cases secretion, of a-hANP in
extracardiac tissues has recently been extensively reviewed [6].
The list of tissue types capable of synthesizing a-hANP seems
to be ever expanding and includes: hypothalamus and various
extra-hypothalamic regions of the brain, the olfactory system,
the peripheral nervous system, spinal cord, pulmonary vein,
vena cava, lung, aorta, pituitary, adrenals, and others [6].
However, ANP immunoreactivity and ANP mRNA concentra-
tion in extracardiac organs are usually very low, and secretory
granules are not present. Thus, it is unlikely that many of these
extracardiac organs significantly contribute to circulating
a-hANP levels.
ANP mRNA and ANP immunoreactivity are also expressed
in the aorta [26]. Westenfelder and Baranowski [22] observed
measurable levels of circulating ANP of non-cardiac origin in
calves with artificial hearts, subsequently identifying an "aortic
ANP system" as a source of this non-cardiac ANP [22].
However, to date, the quantitative contribution to circulating
ANP levels of the aorta in man has not been defined. Thus, the
contribution of the aorta, as well as other extracardiac organs,
to circulating ANP levels in heart disease patients requires
further study.
In summary, the present results demonstrate that the high
circulating venous plasma a-hANP concentrations seen in our
patients with left ventricular dysfunction were primarily due to
increased a-hANP production but in some patients with ad-
vanced cardiac dysfunction a decrease in metabolic clearance
may also be involved. In our patients with cardiac dysfunction,
a substantial amount of a-hANP was released into the circula-
tion from a site or sites other than that released into the right
heart. Thus, although drainage from the right and left heart
occurs into the coronary sinus, in our cardiac dysfunction
patients other left heart and/or extracardiac sites must have
released a-hANP into the circulation.
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